A Phase 1b/2, Multi-center, Single Arm Study to Assess the Safety and Efficacy of Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors

Enrolling by Invitation

PHASE1Ages 12+InterventionalTreatment

Jaime Leandro Foundation for Therapeutic Cancer Vaccines

~136 participants

Updated 2026-01-15 on ClinicalTrials.gov

What's tested:Personalized Synthetic Long Peptide Vaccine

At a glance

Recruiting sites

0 of 5 listed sites are recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

To assess the efficacy of NeoSLP vaccination by investigator assessment of Progression-Free Survival at 12 months (PFS12).

Measured over Until progression or death, assessed up to 12 months post first vaccine administration.

Cancer

Solid Tumor

NCT05741242

This study runs at 5 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

Anna Gattani MD PC
New York, New Yorkno site contact published
Mount Sinai Comprehensive Cancer Center
Miami Beach, Floridano site contact published
Precision NextGen Oncology & Research Center
Beverly Hills, Californiano site contact published
Quest Clinical Research
San Francisco, Californiano site contact published
St. Louis Cancer Care
Bridgeton, Missourino site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

This trial hasn't published a contact. View it on ClinicalTrials.gov

To assess the efficacy of NeoSLP vaccination by investigator assessment of Progression-Free Survival at 12 months (PFS12).Until progression or death, assessed up to 12 months post first vaccine administration.
Progression-Free Survival at 12 months (PFS12) defined as time from first vaccine administration until disease progression by investigator assessment or death due to any cause.